Company Overview and News

 
SNY / Sanofi 6-K (Current Report of Foreign Issuer)

11h sec.gov
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
Mertiva: Strong Insider Buying At A Discount To NAV

2018-05-21 seekingalpha
Note: There is much greater liquidity on the Nordic Growth Market exchange Nordic MTF under the ticker MERT MTF A.

 
Spotlight On Gambling Reset And Banking Bill

2018-05-19 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.

 
SNY / Sanofi SC TO-T/A

2018-05-18 sec.gov
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
SNY / Sanofi SC TO-T/A

2018-05-18 sec.gov
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data

2018-05-17 zacks
Biotech major Amgen Inc. (AMGN - Free Report) gained approval from the European Commission (EC) for its regulatory application seeking approval to include data from the cardiovascular outcomes study, FOURIER, on the European label of its PCSK9 inhibitor, Repatha.

 
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

2018-05-16 zacks
Sanofi (SNY - Free Report) and partner Regeneron Pharmaceuticals (REGN - Free Report) announced that a phase III study evaluating its atopic dermatitis (eczema) drug Dupixent (dupilumab) in adolescent patients (aged 12-17) met its primary and key secondary endpoints.

 
BioMarin Begins Mid Stage Study on Gene Therapy Candidate

2018-05-16 zacks
BioMarin Pharmaceutical Inc. (BMRN - Free Report) initiated dosing its first patient in a phase I/II study – BMN 207-203 – evaluating its gene therapy candidate, valoctocogene roxaparvovec, in severe hemophilia A patients with pre-existing AAV5 antibodies.

2
Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise

2018-05-16 seekingalpha
As a novel molecule (the first-in-class), NKTR-358 has the vast applications in other autoimmune diseases due to its stellar mechanism of action.

6
Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q1 2018 Update

2018-05-16 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to Berkshire Hathaway’s (NYSE:BRK.A) (NYSE:BRK.B) 13F stock portfolio on a quarterly basis. It is based on Warren Buffett’s regulatory 13F Form filed on 05/15/2018. Please visit our Tracking 10 Years Of Berkshire Hathaway's Investment Portfolio article series for an idea on how his holdings have progressed over the years and our previous update for the moves in Q4 2017.

2
Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments

2018-05-15 seekingalpha
Chiasma was able to get the FDA to favorably modify certain endpoints of its SPA-enabled trial.

2
SNY / Sanofi S-8 POS

2018-05-15 sec.gov
S-8 POS Registration No. 333-218099 UNITED STATES

 
SNY / Sanofi SC TO-T/A

2018-05-14 sec.gov
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
SNY / Sanofi SC TO-T/A

2018-05-14 sec.gov
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

 
SANOFI EN ABLYNX KONDIGEN DE SUCCESVOLLE RESULTATEN VAN DE INITIËLE AANVAARDINGSPERIODE VOOR ABLYNX EN DE AANVANG VAN DE SQUEEZE OUT AANVAARDINGSPERIODE AAN

2018-05-14 globenewswire
Parijs, Frankrijk en Gent, België - 14 mei 2018 - Sanofi [Euronext: SAN; NYSE: SNY] en Ablynx [Euronext Brussel en NASDAQ: ABLX] hebben vandaag de resultaten van de initiële aanvaardingsperiode van Sanofi's eerder aangekondigde openbare overnamebiedingen op alle uitstaande aandelen (inclusief de aandelen vertegenwoordigd door American Depositary Shares ("ADS")), warrants en converteerbare obligaties (samen, de "Effecten") van Ablynx aangekondigd.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 80105N105